CDK3抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P03806(CDK3 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

Cyclin-dependent kinase 3 (CDK3) is a member of the CDK family, which plays a critical role in regulating cell cycle progression. Unlike other CDKs like CDK2 or CDK4/6. CDK3 is less studied but has been implicated in facilitating the G1-to-S phase transition by interacting with cyclins such as Cyclin C or E. Its activity is tightly controlled through phosphorylation and binding to endogenous inhibitors like p21 or p27. Research suggests CDK3 may contribute to tumorigenesis, with overexpression observed in cancers like breast, lung, and prostate, where it potentially drives proliferation or chemoresistance. Additionally, CDK3 has been linked to neuronal development and stem cell regulation.

CDK3 antibodies are essential tools for detecting CDK3 protein expression, localization, and interactions in research. These antibodies, often generated in hosts like rabbits or mice, vary in clonality (monoclonal/polyclonal) and applications (Western blotting, immunohistochemistry, flow cytometry). Validation via knockout cell lines or siRNA-mediated knockdown is crucial to confirm specificity, given structural similarities among CDK family members. Commercially available CDK3 antibodies enable studies exploring its biological roles, dysregulation in diseases, and therapeutic targeting. However, limited commercial options and cross-reactivity challenges highlight the need for rigorous validation in experimental settings. Ongoing research aims to clarify CDK3's precise mechanisms and therapeutic potential in oncology and beyond.